The company “Chromis”, resident of the biomedical technologies Cluster of the SKOLKOVO Foundation, received a registration certificate of Ministry of health of the Russian Federation on drug favipiravir. This is the first Russian antivirus preparation of direct actions that violate the mechanisms of reproduction of coronavirus, the report said SKOLKOVO.
Research favipiravir confirmed that the efficacy exceeds the threshold of 80%. In 68% of patients who took favipiravir, the body temperature was normalized earlier (on day 3) than in the control group (on day 6). On average, the liberation of the body from the virus as a result of the use of favipiravir happened for 4 days, while in the group of standard therapy, the average duration is 9 days. Favipiravir has been well studied as of 2014 used in Japan against severe forms of influenza.
In early April, the Supervisory Board of the Russian direct investment Fund (RDIF) approved the establishment of a joint venture (JV) “Chromis” group of companies “Chemrar” for the production of favipiravir and other sorts of innovative medicines, including based on it.